HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

Histone deacetylase inhibitors (HDACi) can modulate innate antiviral responses and render tumors more susceptible to oncolytic viruses (OVs); however, their effects on adaptive immunity in this context are largely unknown. Our present study reveals an unexpected property of the HDACi MS-275 that enhances viral vector-induced lymphopenia leading to selective depletion of bystander lymphocytes and regulatory T cells while allowing expansion of antigen-specific secondary responses. Coadministration of vaccine plus drug during the boosting phase focuses the immune response on the tumor by suppressing the primary immune response against the vaccine vector and enhancing the secondary response against the tumor antigen. Furthermore, improvement of T cell functionality was evident suggesting that MS-275 can orchestrate a complex array of effects that synergize immunotherapy and viral oncolysis. Surprisingly, while MS-275 dramatically enhanced efficacy, it suppressed autoimmune pathology, profoundly improving the therapeutic index.

[1]  R. Caspi,et al.  Immunotherapy of autoimmunity and cancer: the penalty for success , 2008, Nature Reviews Immunology.

[2]  Eleanor Pullenayegum,et al.  Potentiating cancer immunotherapy using an oncolytic virus. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  R. Salomon,et al.  Modulation of STAT1 protein levels: a mechanism shaping CD8 T-cell responses in vivo. , 2006, Blood.

[4]  H. Kohler,et al.  Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. , 2010, Genes & development.

[5]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[6]  David E Levy,et al.  Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  L. Ellis,et al.  Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models , 2012, PloS one.

[8]  Raymond M. Welsh,et al.  Attrition of Bystander CD8 T Cells during Virus-Induced T-Cell and Interferon Responses , 2001, Journal of Virology.

[9]  H. Atkins,et al.  Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors , 2010, PloS one.

[10]  M. Atkins,et al.  Autoimmunity and immunotherapy for cancer. , 2006, The New England journal of medicine.

[11]  H. Schluesener,et al.  MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis , 2010, Neuroscience.

[12]  T. Alain,et al.  Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSVΔM51) on Multifocal and Invasive Gliomas , 2006 .

[13]  G. Barber.  VSV-tumor selective replication and protein translation , 2005, Oncogene.

[14]  G. Lutfalla,et al.  Down-Modulation of Responses to Type I IFN Upon T Cell Activation1 , 2003, The Journal of Immunology.

[15]  Nahum Sonenberg,et al.  Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus , 2000, Nature Medicine.

[16]  C. Mackall,et al.  Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. , 2009, Blood.

[17]  T. Junt,et al.  Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. , 2006, Blood.

[18]  H. Marshall,et al.  Virus-Induced Transient Immune Suppression and the Inhibition of T Cell Proliferation by Type I Interferon , 2011, Journal of Virology.

[19]  E. Sercarz,et al.  Induction of anti-self-immunity to cure cancer , 1995, Cell.

[20]  H. Atkins,et al.  Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis , 2008, Proceedings of the National Academy of Sciences.

[21]  M. Sweet,et al.  Histone deacetylases as regulators of inflammation and immunity. , 2011, Trends in immunology.

[22]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[23]  C. Horvath,et al.  Positive and Negative Regulation of the Innate Antiviral Response and Beta Interferon Gene Expression by Deacetylation , 2006, Molecular and Cellular Biology.

[24]  S. Akira,et al.  Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease , 2005, Nature Medicine.

[25]  B. Pulendran,et al.  Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production , 2010, Proceedings of the National Academy of Sciences.

[26]  T. Suzuki,et al.  Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. , 1999, Journal of medicinal chemistry.

[27]  H. Atkins,et al.  A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  H. Atkins,et al.  Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  A. Meshorer,et al.  Involvement of interferon in virus-induced lymphopenia. , 1983, Cellular immunology.

[30]  S. Rosenberg,et al.  CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.

[31]  Shucui Jiang,et al.  Immunotherapy Can Reject Intracranial Tumor Cells without Damaging the Brain despite Sharing the Target Antigen , 2010, The Journal of Immunology.

[32]  F. Blanchard,et al.  Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? , 2005, Drug discovery today.

[33]  S. Choi,et al.  HDAC Inhibition and Graft Versus Host Disease , 2011, Molecular medicine.

[34]  M. Atkins,et al.  White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy , 2011, Clinical Cancer Research.

[35]  A. Ballestrero,et al.  Histone Deacetylase Inhibitors Affect Dendritic Cell Differentiation and Immunogenicity , 2007, Clinical Cancer Research.

[36]  J. Bramson,et al.  Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin , 2004, Cancer Research.

[37]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[38]  T. Fry,et al.  Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. , 2005, The Journal of clinical investigation.

[39]  E. Gilboa.  The risk of autoimmunity associated with tumor immunotherapy , 2001, Nature Immunology.

[40]  Luigi Naldini,et al.  FcRgamma activation regulates inflammation-associated squamous carcinogenesis. , 2010, Cancer cell.

[41]  E. Sgouroudis,et al.  Single-Cell Analysis of the Human T Regulatory Population Uncovers Functional Heterogeneity and Instability within FOXP3+ Cells , 2011, The Journal of Immunology.

[42]  T. Tedder,et al.  Regulatory B cells as inhibitors of immune responses and inflammation , 2008, Immunological reviews.

[43]  M. Roederer,et al.  T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.

[44]  R. Dana,et al.  Levels of Foxp3 in Regulatory T Cells Reflect Their Functional Status in Transplantation1 , 2009, The Journal of Immunology.

[45]  H. Atkins,et al.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. , 2003, Cancer cell.

[46]  N. Restifo,et al.  Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". , 2000, Critical reviews in immunology.

[47]  I. Adcock.  Histone deacetylase inhibitors as novel anti-inflammatory agents. , 2006, Current opinion in investigational drugs.

[48]  C. Peacock,et al.  Attrition of Virus-Specific Memory CD8+ T Cells During Reconstitution of Lymphopenic Environments1 , 2003, The Journal of Immunology.

[49]  R. Baron,et al.  Anti‐rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen‐induced arthritis in rodents , 2007, British journal of pharmacology.

[50]  Hao Shen,et al.  Selective Depletion of Nonspecific T Cells During the Early Stage of Immune Responses to Infection 1 , 2003, The Journal of Immunology.